Class Action Lawsuit Filed Against 3D Systems Corporation for Securities Law Violations

Strategic Insights -

3D Systems Corporation, a leading provider of 3D printing and digital manufacturing solutions, has been sued in a class action lawsuit by investors who purchased or acquired the company's securities between August 13, 2024, and May 12, 2025. The lawsuit, filed in the United States District Court for the District of Delaware, alleges that the company and its top officials made materially false and misleading statements regarding the business, operations, and compliance policies. The class action seeks to recover damages caused by the defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

Key Takeaways:

  • The lawsuit alleges that 3D Systems Corporation made false and/or misleading statements and/or failed to disclose that the company had understated the impact of weakened customer spending on its business, while overstating its resilience in challenging industry conditions.
  • The lawsuit also alleges that the company's Regenerative Medicine Program revenue was negatively impacted by the updated milestone criteria in its partnership with United Therapeutics Corporation.
  • The company's stock price fell after the company released its financial results for the fourth quarter and full-year 2024, which included a $9 million revenue reduction in Q4 due to a change in accounting estimates for the Regenerative Medicine program.
  • The company's stock price fell again after the company released its financial results for the first quarter of 2025, which included a revenue decline of 8% year-over-year and a net loss of $37 million.
  • The lawsuit seeks to recover damages for investors who purchased or acquired 3D Systems securities during the Class Period.
  • The lawsuit also alleges that the company and its top officials made false and/or misleading statements and/or failed to disclose that the company was experiencing prolonged softness in customer capital spending and macroeconomic uncertainty.

Statistics:

  • The class action lawsuit was filed in the United States District Court for the District of Delaware on July 28, 2025.
  • The lawsuit covers all persons and entities other than defendants that purchased or acquired 3D Systems securities between August 13, 2024, and May 12, 2025.
  • The company's stock price fell $0.57 per share, or 20.96%, to close at $2.15 per share on March 27, 2025, after the company released its financial results for the fourth quarter and full-year 2024.
  • The company's stock price fell $0.68 per share, or 26.6%, to close at $1.87 per share on May 13, 2025, after the company released its financial results for the first quarter of 2025.
  • The company reported Q4 non-GAAP earnings-per-share of -$0.19, missing consensus estimates by $0.08 per share, and sales revenue of $111 million, representing a -3.4% year-over-year decline and missing consensus estimates by $4.17 million.
  • The company reported a $9 million revenue reduction in Q4 driven by a change in accounting estimates for its Regenerative Medicine program.
  • The company attributed its disappointing results, in part, to a decline in material sales, mostly due to inventory management issues in the dental portion of its Healthcare Solutions segment.

Sources:

  • Pomerantz LLP, "Pomerantz Law Firm Announces the Filing of a Securities Class Action Against 3D Systems Corporation. Pomerantz LLP - New York, NY"
  • GlobeNewswire, "Pomerantz Announces Filing of Class Action Lawsuit Against 3D Systems Corporation and Certain Officers"
  • 3D Systems Corporation, "3D Systems Reports Q4 and Full-Year 2024 Results"
  • 3D Systems Corporation, "3D Systems Reports Q1 2025 Results"